Poor prognosis AML or MDS

Histological confirmation of diagnosis

White blood cell count less than or equal to 30,000/mm3

Adequate hepatic and renal function documented within 14 days prior to registration

Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

No evidence of preexisting uncontrolled hypertension

Not a suitable candidate for chemotherapy

No prior systemic chemotherapy treatment for AML or MDS or treatment with an anti-angiogenesis agent

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)